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CONTRIBUTION
What are the novel findings of this work?
Several studies have suggested that human chorionic
gonadotropin (hCG) concentration is associated with
pregnancy outcomes, including pre-eclampsia. However,
the underlying mechanisms remain largely unexplained.
This study shows an association of high total hCG with
a high risk of pre-eclampsia, which could be explained in
part by the effects of hCG on the balance between pro-
and anti-angiogenic factors, placental growth factor and
soluble fms-like tyrosine kinase-1.
What are the clinical implications of this work?
The results of this study, showing the association of high
hCG concentration with risk of pre-eclampsia, could be
incorporated into clinical prediction models. This means
that, by using hCG concentration profile, together with
other risk factors, the probability of adverse events in
pregnancy, including the risk of developing pre-eclampsia,
could be analyzed.
ABSTRACT
Objectives Abnormal placentation in early pregnancy
may play a role in the pathogenesis of pre-eclampsia.
Human chorionic gonadotropin (hCG) regulates placental
development and angiogenesis and may affect the ratio of
soluble fms-like tyrosine kinase-1 (sFlt-1) and placental
growth factor (PlGF) in the serum. The aims of this study
were to investigate the association of total hCG with the
risk of pre-eclampsia and to examine the potential effect
of pro- and anti-angiogenic factors on this association.
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Methods This was a population-based prospective cohort
study of 7754 women with a singleton pregnancy.
Total hCG was measured in the first available sam-
ple (median gestational age, 14.4 weeks; 95% range,
10.1–26.1 weeks) and sFlt-1 and PlGF concentrations
in early (< 18 weeks; median, 13.2 weeks; 95% range,
9.6–17.6 weeks) and in mid- (18–25 weeks; median,
20.4 weeks; 95% range, 18.5–23.5 weeks) pregnancy. We
tested the association of hCG concentration and risk
of pre-eclampsia using regression analysis, adjusting for
maternal age, ethnicity, body mass index, parity, edu-
cation level, smoking status and fetal sex. Additionally,
we assessed whether this association was affected by the
sFlt-1/PlGF ratio.
Results High hCG concentration was associated with a
1.5–2.7-fold increased risk of pre-eclampsia (P = 0.0001),
depending on the cut-off used, and with increased sFlt-1/
PlGF ratio during early pregnancy (P < 0.0001). The asso-
ciation between high hCG and pre-eclampsia attenuated
by roughly 40% after adjustment for early-pregnancy
sFlt-1/PlGF ratio (β-estimate change from 0.19 ± 0.10
(P = 0.052) to 0.12 ± 0.10 (P = 0.22)).
Conclusions High total hCG concentration in early
pregnancy is associated with an increased risk of
pre-eclampsia. The effect of high hCG concentration
on the balance between pro- and anti-angiogenic factors
during pregnancy may have a role in the pathophysiology
of pre-eclampsia. © 2019 The Authors. Ultrasound in
Obstetrics & Gynecology published by John Wiley &
Sons Ltd on behalf of the International Society of
Ultrasound in Obstetrics and Gynecology.
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INTRODUCTION
Pre-eclampsia is a multisystem disorder defined as
new-onset hypertension and proteinuria after the
20th week of pregnancy1. Pre-eclampsia occurs in 2–8%
of pregnancies and is a major cause of maternal mor-
bidity and adverse perinatal outcome, accounting for
10–15% of maternal deaths2. In this life-threatening
condition, maternal complications arise from excessive
inflammation and endothelial damage to multiple organs,
including the placenta2. The known risk factors for
pre-eclampsia include nulliparity, age over 40 years and
pre-existing conditions including hypertension, renal dis-
ease and diabetes2.
Although the exact pathophysiological mechanism is
unclear, it is postulated that abnormal placentation in
early pregnancy predisposes women to pre-eclampsia2
and that disturbance in the balance between pro-
and anti-angiogenic factors plays an important role3,4.
Placental growth factor (PlGF), a member of the
vascular endothelial growth factor (VEGF) family and
a pro-angiogenic factor, is expressed in the placenta
throughout pregnancy5. Soluble fms-like tyrosine kinase-1
(sFlt-1) is a potent anti-angiogenic factor that binds
VEGFs, including PlGF, thereby inhibiting angiogenesis
during pregnancy6. An abnormal serum sFlt-1/PlGF
ratio, with low concentrations of PlGF and elevated
concentrations of sFlt-1, often occurs in pre-eclamptic
women and may be a marker of impaired placentation7,8.
Human chorionic gonadotropin (hCG), a pregnancy-
specific hormone produced by trophoblast cells, regulates
progesterone production, implantation, uterine growth
and immune cell function9. hCG also regulates placental
development, angiogenesis and vasculogenesis, partially
via effects on VEGFs10–14. Several studies suggest that
high and/or low hCG concentration is a marker of
subsequent clinical manifestation of pre-eclampsia15–18.
However, considerable between-study discrepancies exist,
such as the gestational age at hCG measurement, the
specific hCG isoform that was assessed and the specific
pre-eclampsia phenotype analyzed15–20. To our know-
ledge, no study has investigated the potential effect of early
placental function markers that may predispose women
to pre-eclampsia, such as the sFlt-1/PlGF ratio, on the
association between hCG and the risk of pre-eclampsia.
In the current study, we aimed to investigate the
associations of total hCG concentration with the
sFlt-1/PlGF ratio and the risk of subsequent pre-eclampsia,
in a large population-based prospective cohort.
SUBJECTS AND METHODS
Study population
This study was embedded in Generation R, a population-
based prospective cohort study of pregnancies fol-
lowed from early gestation onwards, in Rotterdam,
The Netherlands21. This cohort study was designed to
assess early environmental and genetic determinants of
pre- and postnatal growth, development and health21.
In this study, 8879 pregnant women with an expected
delivery date between April 2002 and January 2006
were eligible and enrolled21. Women who had undergone
in-vitro fertilization (n = 38), twin pregnancies (n = 91)
and women with pre-existing hypertension (n = 135) were
excluded from the analysis. Total hCG was determined
in all first available serum samples and was available in
7754 women22.
The general design, research aims and specific measure-
ments in the Generation R study have been approved by
the Medical Ethics Committee of the Erasmus Medical
Center, Rotterdam (date: 17 December 2001). Written
informed consent was obtained from all participants.
hCG measurements
Total hCG was measured in first available samples
(median gestational age, 14.4 weeks; 95% range, 10.1–
26.1 weeks) using a solid-phase two-site chemilumines-
cence immunometric assay, calibrated against World
Health Organization Third International Standard
75/537, on an Immulite 2000 XPi system (Siemens
Healthcare Diagnostics, Deerfield, IL, USA). The assay
detects serum intact hCG, hyperglycosylated hCG, serum
nicked hCG, serum nicked hyperglycosylated hCG,
serum asialo hCG, serum hCG free β-subunit and serum
nicked hCG β. The intra-assay variation coefficients were
8.0%, 6.3% and 5.1% at concentrations of 9.7, 53.1 and
821.5 IU/L, respectively. hCG concentration was stan-
dardized by calculating SD scores adjusted for gestational
age at blood sampling, as described previously22.
Pre-eclampsia
Pre-eclampsia diagnosis was confirmed by a certified
medical doctor, blinded to analyte results, by reviewing
hospital charts23, and was defined, according to the
criteria of the International Society for the Study of
Hypertension in Pregnancy, as the development of systolic
blood pressure (BP) of ≥ 140 mmHg and/or diastolic BP of
≥ 90 mmHg (on at least two BP readings) after 20 weeks
of gestation in a previously normotensive woman, and
the presence of proteinuria (defined as two or more
dipstick readings of ≥ 2, one catheter sample reading
of ≥ 1 or a 24-h urine collection containing ≥ 300 mg of
protein)1. Pregnancy-induced hypertension was defined
as development of systolic BP of ≥ 140 mmHg and/or
diastolic BP of ≥ 90 mmHg (on at least two BP readings)
after 20 weeks of gestation in a previously normotensive
woman, without the presence of proteinuria1.
Angiogenic factor measurements
sFlt-1 and PlGF concentrations were obtained from
EDTA blood samples taken in early (< 18 weeks;
median, 13.2 weeks; 95% range, 9.6–17.6 weeks) and
mid- (18–25 weeks; median, 20.4 weeks; 95% range,
18.5–23.5 weeks) pregnancy and were analyzed using a
© 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 54: 477–483.
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microparticle-enhanced immunoassay on the Architect
System (Abbott Diagnostics BV, Hoofddorp, The Nether-
lands). The between-run coefficients of variation for
sFlt-1 were 2.8% at 5.5 ng/mL and 2.3% at 34.0 ng/mL.
The between-run coefficients for PlGF were 4.7% at
24 pg/mL and 3.8% at 113 pg/mL. Measurements were
available for 70.8% and 87.5% of women for the first
and second timepoint, respectively (non-response analysis
is shown in Table S1). For measurement, we calculated
the ratio of sFlt-1 and PlGF, which is a clinical factor
that can be used to predict the risk of pre-eclampsia7,8.
Covariates
Information on maternal age, educational level, ethnicity
and smoking status was obtained by questionnaires dur-
ing pregnancy. Ethnicity was determined according to the
woman’s country of origin and defined according to the
classification of Statistics Netherlands. Maternal smoking
status was classified as non-smoker, smoker until known
pregnancy or continued smoker during pregnancy21.
Information on in-vitro fertilization treatment, parity and
sex of the child was obtained from community midwifery
and hospital registries.
Statistical analysis
The association of hCG with sFlt-1/PlGF ratio was
investigated using multiple linear regression models.
The association of hCG with pre-eclampsia and
pregnancy-induced hypertension was investigated using
multiple logistic regression analyses. Restricted cubic
splines utilizing three or four knots were used to assess
possible non-linearity. Subsequently, to further quantify
the risk of pre-eclampsia, odds ratios were calculated for
the upper and lower 5th, 10th and 15th percentile cut-offs
for hCG concentration. Multivariable associations were
depicted graphically by plots, and β-estimates with
95% CI are shown in Table S2. Full model estimates are
shown in Tables S3–S5. For linear regression models, the
assumption of normality of standardized residuals of the
model was tested. Effect modification by gestational age
at blood sampling or fetal sex was tested by introducing to
the model a product interaction term of hCG × gestational
age at blood sampling or hCG × fetal sex, and a P-value
of < 0.15 was considered for stratification.
All model covariates were selected based on biological
plausibility, change in the effect estimate or residual
variability of the model. All analyses were adjusted for
maternal age, ethnicity, body mass index (BMI), parity,
educational level, smoking status and fetal sex.
In order to cope with missing data on the covari-
ates, multiple imputation was performed according
to the Markov Chain Monte Carlo method24. Before
imputation, exploratory analyses were performed by
investigating the pattern of missingness for each variable.
All variables showed a random missingness pattern. The
percentage of missing data was less than 1% for maternal
age, BMI, parity and fetal sex, 5.3% for ethnicity, 8.8%
for education level and 12.6% for smoking status. Five
imputed datasets were created and pooled for analysis.
hCG concentration adjusted for gestational age at
measurement and the risk of pre-eclampsia were used
as predictor variables only. There were no differences
in descriptive characteristics between the original and
imputed datasets.
Statistical analyses were performed using SPSS
Statistics for Windows version 21.0 (IBM Corp.,
Armonk, NY, USA) and R statistical software version
3.2.1 (R Foundation for Statistical Computing, Vienna,
Austria; package ‘rms’).
RESULTS
After exclusions, the final population comprised 7754
women (Figure 1), the characteristics of whom are
shown in Table 1. There were 165 (2.2%) women who
developed pre-eclampsia, 4287 (55.3%) women who were
nulliparous, and the population was predominantly of
Dutch origin (3762; 48.5%) (Table 1).
Association of hCG with angiogenic factors
There was a positive association between hCG and
sFlt-1/PlGF ratio during early pregnancy (P < 0.0001;
Figure 2a). The positive association between hCG and
sFlt-1/PlGF ratio during mid-pregnancy (P = 0.0002,
Figure 2b) attenuated after adjustment for sFlt-1/PlGF
ratio at inclusion (P = 0.29; Figure 2c). There was no
association between hCG and  (the difference between
Women enrolled during
pregnancy
(n = 8879)
Unable to perform hCG measurement
(mainly due to non-availability of
serum, discontinuation of study
participation, lab measurement errors)
 (n = 685)
hCG measurement
performed
(n = 8194)
Excluded (n = 440):
• In-vitro fertilization (n = 38)
• Twin pregnancy (n = 91)
• Pre-existing hypertension (n = 135)
• Non-availability of data on
 hypertensive disorder (n = 176)
Population with available
data for analysis
(n = 7754)
Figure 1 Flowchart showing selection procedure of study
population of pregnant women with available data on human
chorionic gonadotropin (hCG) and angiogenic factors.
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Table 1 Demographic and clinical characteristics of 7754
pregnancies
Characteristic Value
hCG (IU/L) 35 522.0 (6074.9–99 890.3)
GA at blood sampling (weeks) 14.4 (10.1–26.1)
Hypertensive disorder in pregnancy
Pre-eclampsia 165 (2.2)
Pregnancy-induced hypertension 286 (3.7)
No disorder 7303 (94.2)
sFlt-1/PlGF ratio
< 18 weeks 117.0 (19.5–432.6)
18–25 weeks 24.4 (5.3–106.8)
Maternal age (years) 29.6 ± 5.3
BMI (kg/m2) 24.7 ± 4.4
Parity
Nulliparous 4287 (55.3)
Primiparous 2325 (30.0)
Multiparous 1142 (14.7)
Smoking status
Non-smoker 5659 (73.0)
Stopped smoking 676 (8.7)
Smoker 1419 (18.3)
Educational level
None or primary education 952 (12.3)
Secondary education 3651 (47.1)
Higher education 3151 (40.6)
Ethnicity
Dutch 3762 (48.5)
Moroccan 557 (7.2)
Turkish 763 (9.8)
Surinamese 705 (9.1)
Asian 441 (5.7)
Other European 598 (7.7)
Other non-European 928 (12.0)
Fetal sex
Male 3911 (50.4)
Female 3843 (49.6)
Data are shown as median (95% range), n (%) or mean ± SD. BMI,
body mass index; GA, gestational age; hCG, human chorionic
gonadotropin; PlGF, placental growth factor; sFlt-1, soluble
fms-like tyrosine kinase-1.
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Figure 2 Association of total human chorionic gonadotropin (hCG) concentration with early- (< 18 weeks; P < 0.0001 (a)) and mid-
(18–25 weeks; P = 0.0002 (b)) pregnancy soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio, and mid-pregnancy
sFlt-1/PlGF ratio adjusted for measurement at inclusion (P = 0.29 (c)). Plots show predicted mean with 95% CI calculated using linear
regression models. Analyses were adjusted for ethnicity, body mass index, maternal age, fetal sex, educational level, parity and smoking
status.
first and second measurements) sFlt-1/PlGF ratio after
adjustment for sFlt-1/PlGF ratio at inclusion (P = 0.29;
Figure S1). The associations of hCG with PlGF and sFlt-1
individually are shown in Figures S2 and S3, respectively.
Association of hCG with pre-eclampsia
Figure 3 shows the association between hCG and the risk
of pre-eclampsia. High hCG concentration was associated
with a 1.5–2.7-fold increased risk of pre-eclampsia,
depending on the hCG cut-off value used (Figure 3).
After addition of a product interaction term to the model
(hCG × fetal sex, P = 0.020), we stratified the association
between hCG and the risk of pre-eclampsia according
to fetal sex, which showed a stronger association of high
hCG with the risk of pre-eclampsia in pregnancies with
a male fetus (4.0-fold increased risk in males vs 2.2-fold
increased risk in females when hCG concentration
was greater than the highest 5th percentile; Figure S4).
We did not observe effect modification according to
gestational age (hCG × gestational age, P = 0.73; data
not shown). Furthermore, when sFlt-1/PlGF ratio was
adjusted for (in the subgroup of women with available
data on angiogenic factors), the association between
hCG and pre-eclampsia attenuated by 40% (β-estimate
change from 0.19 ± 0.10 (P = 0.052) to 0.12 ± 0.10
(P = 0.22)).
The association of hCG with the risk of pregnancy-
induced hypertension (Figure S5) showed a similar trend,
although it did not reach statistical significance.
DISCUSSION
In this study, we demonstrated associations of high
total hCG concentration with high sFlt-1/PlGF ratio and
increased risk of pre-eclampsia. Our results suggest that up
to 40% of the association between hCG and pre-eclampsia
© 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 54: 477–483.
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Figure 3 Association of total human chorionic gonadotropin (hCG) concentration with risk of pre-eclampsia (P = 0.0001). Plot shows
predicted mean with 95% CI calculated using regression model. Analyses were adjusted for ethnicity, body mass index, maternal age, fetal
sex, educational level, parity and smoking status. Cut-offs for calculation of odds ratios (OR) are based on percentiles of total hCG
standardized for gestational age.
might be mediated via effects of hCG on the angiogenic
factors sFlt-1 and PlGF.
Pre-eclampsia is an important cause of maternal and
fetal morbidity and mortality1,2,25,26. Great effort has
been put into investigating the pathophysiological mech-
anisms leading to pre-eclampsia and the clinical markers
of this condition2. Although the exact mechanism
remains to be elucidated, abnormal placentation and a
subsequent hyperinflammatory response, characterized
by a disturbance in pro- and anti-angiogenic factors, play
a major role2–4. Multiple studies have investigated the
association of hCG with the risk of pre-eclampsia, com-
prising data on different hCG isoforms15–20,27. Although
in early and in late pregnancy high total hCG and β-hCG
concentrations are suggested as a marker of (subsequent)
pre-eclampsia15–18, some studies report an association of
low early-pregnancy β-hCG19,27 and hyperglycosylated
hCG with pre-eclampsia20. The interpretation and com-
parison of these studies are hampered by the differences in
hCG measurement. Most studies utilize β-hCG, which is
often measured in the setting of screening or as biochemi-
cal proof of pregnancy. However, different hCG isoforms
predominate during distinct phases of gestation28,29, and
studies measuring only the β-hCG isoform may therefore
have different results as compared with those in the
current study in which total hCG was measured. Future
studies meta-analyzing individual participant data could
prove useful in elucidating the magnitude of the effect of
these differences on the association with pre-eclampsia
and delineate the extent to which discrepancies in
associations with clinical outcome could be explained by
variation in hCG isoform, gestational age, assay used or,
for example, potential placental, endocrine or vascular
factors that we could not identify.
In pre-eclamptic women, the sFlt-1/PlGF ratio is higher
than in healthy women7,30,31. It is considered that high
production of sFlt-1 in the placenta largely counteracts
the effects of PlGF and thereby contributes to the devel-
opment of hypertension and proteinuria6. In pathological
states characterized by high hCG concentration, such as
molar pregnancy, which predisposes to pre-eclampsia,
the expression of placental sFlt-1 is higher compared
with that of PlGF32,33. As hCG may play a role in
the regulation of placental angiogenesis via effects on
the production of VEGFs10–14, we hypothesized that
abnormal hCG concentration may be a contributing
factor to the unfavorable balance in the expression of
placental pro- and anti-angiogenic factors in women with
pre-eclampsia.
There may be an additional underlying mechanism
contributing to the association of high hCG con-
centration with the increased risk of pre-eclampsia,
such as hCG-modulating effects on immune cells,
which may respond differently depending on the hCG
concentration34. In general, hCG has a protective effect
on pregnancy and promotes fetal survival by promoting
immune tolerance via interaction with macrophages,
natural killer cells, and B- and T-lymphocytes34. How-
ever, in higher doses, hCG may exhibit harmful effects
on fetal development35,36 and may induce an immune
cell response with altered cytokine and reactive oxygen
species production37, triggering exaggerated sFlt-1
production and thereby reinforcing the cumulative effect
of factors predisposing women to pre-eclampsia38. Alter-
natively, higher availability of sFlt-1 and anti-angiogenic
effects characterizing pre-eclampsia might be due to
hCG-stimulated binding of PlGF to membrane and local
circulating receptors4,10–14. Moreover, it has been pro-
posed that dysregulation of not only the concentration of
© 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2019; 54: 477–483.
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hCG but also its glycosylation pattern might underlie the
pathophysiological events and impaired angiogenic and
immune response in pre-eclampsia39. Despite its known
pro-angiogenic effects in normal pregnancy, the effects
of altered hCG concentration on the cross-talk between
trophoblast, endothelial cells and the immune system
in women with pre-eclampsia are poorly understood39.
Therefore, future studies should further elucidate the
multifactorial risk-factor profile of the association of
hCG with pre-eclampsia.
In an attempt to diminish the adverse effects of oxidative
stress and hypertension in women with pre-eclampsia, a
series of maternal compensatory responses may arise40,41.
The association of high hCG concentration with an
increased risk of pre-eclampsia could therefore also repre-
sent a compensatory response of the trophoblast cells to
fetoplacental hypoxia, in which high hCG concentration
is supposed to stimulate angiogenic factor expression
and improve placental function5,6,10,14. Another relevant
determinant of adaptive mechanisms in pregnancy is
fetal sex, as hCG concentration is dependent on fetal
sex42,43. We demonstrated that in women with high hCG
concentration, those with a male fetus have a higher risk
of pre-eclampsia than those with a female fetus. This
might be explained by a potentially greater susceptibility
of male fetuses to the impact of hCG variation, or by
fetal-sex-specific differences in the variation of hCG
isoforms22. The hypothesis of fetal-sex-specific differences
is further supported by our previous study that showed
that the association of low hCG with lower fetal growth
is stronger in pregnancies with a male fetus44.
We were able to perform analyses using prospectively
collected data on measurements of total hCG, rather
than only on a single isoform, and also had detailed data
available on pre-eclampsia and relevant covariates in a
large population. We were limited by the fact that we
had only a single hCG measurement available for each
woman, rendering us unable to examine inter-individual
differences in hCG variation during pregnancy. Future
studies may want to assess whether hCG trajectory is
associated with pre-eclampsia. Another potential limita-
tion could be the availability of data on PlGF and sFlt-1 in
70.8% of the study population, which could potentially
introduce bias. However, a non-response analysis showed
no difference in mean hCG concentrations or in the
frequency of pre-eclampsia between participants with
and those without available data on PlGF and sFlt-1.
Finally, the current study is observational and thus does
not allow for inference about causality and does not
exclude residual confounding.
This study of a healthy population of pregnant
women demonstrates that high hCG concentration in
early pregnancy is associated with an increased risk of
pre-eclampsia. The effect of high hCG concentration on
the balance between pro- and anti-angiogenic factors
during pregnancy might partially explain this finding.
Future studies may want to assess if these findings
could be incorporated into clinical prediction models for
hypertensive disorders of pregnancy.
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18–25 weeks’ gestation
Table S5 Linear regression model for association of maternal hCG (SD) with sFlt-1/PlGF ratio at
18–25 weeks’ gestation, adjusted for baseline measurement
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